LONDON (ShareCast) - (Sharecast News) - Clinical stage biotechnology company PureTech Health said on Tuesday that it had received $45m from the sale of 555,500 shares of its founded entity Karuna Therapeutics.
Following the transaction, PureTech will continue to hold 4.73m shares in Karuna, equal to 18.1% of the group, and has a right to royalty payments on net sales of any commercialised product covered by a license granted by PureTech to Karuna.

The FTSE 250-listed group intends to use the proceeds from the transaction to fund its growth potential.

PureTech has generated over $255m in the past six months from the combined sales of minority portions of founded entity shares.

As of 0850 BST, PureTech shares were up 1.42% at 252.03p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE